A new study by physicians in New Jersey at the University of Medicine and Dentistry (UMDNJ)–Robert Wood Johnson Medical School has identified a drug that may be effective in smoking cessation treatment for patients with schizophrenia or schizoaffective disorder without causing unnecessary harm and symptoms.
"Individuals with schizophrenia/schizoaffective disorder have a greater severity of nicotine dependence and therefore require a more potent treatment plan than the general population," said lead investigator Jill M. Williams, who is also an associate professor of psychiatry at the University.
View Article
